"Metformin: na pomez\u00ED diabetologie a onkologie"@cs . "CZ - \u010Cesk\u00E1 republika" . . . "4" . "3"^^ . "metformin; antidiabetic therapy; cancer; type 2 diabetes mellitus"@en . "Onemocn\u011Bn\u00ED diabetem 2. typu p\u0159edstavuje samo o sob\u011B predispozici k manifestaci n\u00E1dorov\u00E9ho onemocn\u011Bn\u00ED. L\u00E9ky, kter\u00E9 stimuluj\u00ED sekreci inzul\u00EDnu, stejn\u011B jako pod\u00E1v\u00E1n\u00ED inzul\u00EDnu tak\u00E9 m\u00EDrn\u011B zvy\u0161uje riziko onemocn\u011Bn\u00ED n\u00E1dorem (OR okolo 1,3). Pod\u00E1n\u00ED pyoglitazonu dle n\u011Bkter\u00FDch zpr\u00E1v vede k zv\u00FD\u0161en\u00ED rizika karcinomu mo\u010Dov\u00E9ho m\u011Bch\u00FD\u0159e. Naopak \u0159ada studi\u00ED na izolovan\u00FDch bu\u0148k\u00E1ch, experiment\u00E1ln\u00EDch modelech i retrospektivn\u00EDch studi\u00ED u lid\u00ED prok\u00E1zala z\u0159eteln\u00FD preventivn\u00ED \u00FA\u010Dinek metforminu na manifestaci n\u00E1dorov\u00E9ho onemocn\u011Bn\u00ED, zejm\u00E9na n\u00E1dor\u016F pankreatu, prsu, kolorekt\u00E1ln\u00EDho karcinomu, endometria a ovaria. Nav\u00EDc, progn\u00F3za u pacient\u016F s \u0159adou n\u00E1dor\u016F, kte\u0159\u00ED krom\u011B b\u011B\u017En\u00E9 protin\u00E1dorov\u00E9 l\u00E9\u010Dby u\u017E\u00EDvaj\u00ED metformin, se zd\u00E1 z\u0159eteln\u011B lep\u0161\u00ED ne\u017E u pacient\u016F s diabetem, kte\u0159\u00ED metformin neu\u017E\u00EDvaj\u00ED. Tyto v\u00FDsledky d\u00E1vaj\u00ED nad\u011Bji na pou\u017Eit\u00ED metforminu nebo jeho deriv\u00E1t\u016F v prevenci a l\u00E9\u010Db\u011B n\u011Bkter\u00FDch n\u00E1dor\u016F." . "3"^^ . . . "87532" . "Metformin: na pomez\u00ED diabetologie a onkologie" . . "Trnka, Jan" . . "And\u011Bl, Michal" . . . "1211-9326" . "Metformin between diabetology and oncology"@en . "Diabetologie, metabolismus, endokrinologie, v\u00FD\u017Eiva" . "Metformin between diabetology and oncology"@en . "[8231204ABBD9]" . . . . . "16" . "Onemocn\u011Bn\u00ED diabetem 2. typu p\u0159edstavuje samo o sob\u011B predispozici k manifestaci n\u00E1dorov\u00E9ho onemocn\u011Bn\u00ED. L\u00E9ky, kter\u00E9 stimuluj\u00ED sekreci inzul\u00EDnu, stejn\u011B jako pod\u00E1v\u00E1n\u00ED inzul\u00EDnu tak\u00E9 m\u00EDrn\u011B zvy\u0161uje riziko onemocn\u011Bn\u00ED n\u00E1dorem (OR okolo 1,3). Pod\u00E1n\u00ED pyoglitazonu dle n\u011Bkter\u00FDch zpr\u00E1v vede k zv\u00FD\u0161en\u00ED rizika karcinomu mo\u010Dov\u00E9ho m\u011Bch\u00FD\u0159e. Naopak \u0159ada studi\u00ED na izolovan\u00FDch bu\u0148k\u00E1ch, experiment\u00E1ln\u00EDch modelech i retrospektivn\u00EDch studi\u00ED u lid\u00ED prok\u00E1zala z\u0159eteln\u00FD preventivn\u00ED \u00FA\u010Dinek metforminu na manifestaci n\u00E1dorov\u00E9ho onemocn\u011Bn\u00ED, zejm\u00E9na n\u00E1dor\u016F pankreatu, prsu, kolorekt\u00E1ln\u00EDho karcinomu, endometria a ovaria. Nav\u00EDc, progn\u00F3za u pacient\u016F s \u0159adou n\u00E1dor\u016F, kte\u0159\u00ED krom\u011B b\u011B\u017En\u00E9 protin\u00E1dorov\u00E9 l\u00E9\u010Dby u\u017E\u00EDvaj\u00ED metformin, se zd\u00E1 z\u0159eteln\u011B lep\u0161\u00ED ne\u017E u pacient\u016F s diabetem, kte\u0159\u00ED metformin neu\u017E\u00EDvaj\u00ED. Tyto v\u00FDsledky d\u00E1vaj\u00ED nad\u011Bji na pou\u017Eit\u00ED metforminu nebo jeho deriv\u00E1t\u016F v prevenci a l\u00E9\u010Db\u011B n\u011Bkter\u00FDch n\u00E1dor\u016F."@cs . . . . . . . "Metformin: na pomez\u00ED diabetologie a onkologie"@cs . "Type 2 diabetes moderately increases predisposition for manifestation of tumor disease. Both drugs stimulating insulin secretion (insulin secretagogues) and insulin injection therapy also moderately increases risk of tumor manifestation (OR approx. 1,3). According to some reports pyoglitazon therapy could be of increased risk of bladder cancer. On the other hand, hunderds of study on isolated cells, experimental animal models and retrospective studies in patients have shown preventive effect of metformin therapy on mafestation tumors of pankreas, breast, colorectum, liver, endometrium and ovary. More over, the prognosis of diabetic cancer patients on mertformin therapy seems be better, than in diabetics without metformin treatment. These data are promising for future use of metformin for prevention and therapy of some malignant tumors."@en . "\u0160krha, Pavel" . "I, P(NT12407)" . "11120" . "RIV/00216208:11120/13:43908091" . . . "Metformin: na pomez\u00ED diabetologie a onkologie" . "RIV/00216208:11120/13:43908091!RIV14-MZ0-11120___" . "6"^^ .